NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,544.84 +337.71 (+1.85%) CRUDE OIL
79.18 +0.23 (+0.29%) GOLD FUTURES
2,311.90 +2.30 (+0.10%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,242.35 +1,687.35 (+3.70%)
Gilead Sciences, Inc. (0QYQ.IL)
| Previous close | 65.38 |
| Open | 0.00 |
| Bid | 62.22 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 51,015 |
| Market cap | 81.514B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 15.04 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.00 (3.81%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
- Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
- Business Wire
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
- Business Wire
Gilead Sciences Announces First Quarter 2024 Financial Results
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
